Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TK1 | P04183 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18912265 | 0.90 | LMNA (0.67) | LMNASMN1; SMN2TK1TK2RNASE1 | |
| SCHEMBL17122961 | 0.90 | LMNA (0.54) | LMNASMN1; SMN2TK1MAPTESR1 | |
| SCHEMBL15448880 | 0.88 | TK1 (0.57) | LMNATK1RNASE1PMP22 | |
| SCHEMBL14867212 | 0.88 | TK1 (0.57) | LMNATK1RNASE1PMP22 | |
| SCHEMBL25492088 | 0.84 | LMNA (0.58) | LMNASMN1; SMN2TK1MAPTTK2 | |
| SCHEMBL16311910 | 0.84 | LMNA (0.57) | LMNASMN1; SMN2TK1MAPTTK2 | |
| SCHEMBL25492060 | 0.82 | LMNA (0.55) | LMNASMN1; SMN2TK1MAPTTK2 | |
| SCHEMBL16311911 | 0.81 | LMNA (0.80) | LMNASMN1; SMN2TK1TK2TSHR | |
| SCHEMBL18325608 | 0.81 | LMNA (0.80) | LMNASMN1; SMN2TK1TK2TSHR | |
| SCHEMBL25492063 | 0.81 | LMNA (0.80) | LMNASMN1; SMN2TK1TK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100151001-A1 | ETHYNYLATED HETERODINUCLEOSIDE PHOSPHATE ANALOGS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | EBERHARD KARLS UNIVERSITAT TUBINGEN (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151001-A1 | ETHYNYLATED HETERODINUCLEOSIDE PHOSPHATE ANALOGS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | ENTPD5, NUDT1, ENPP1 | LMNA 2372/4885SMN1; SMN2 3633/4885TK1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.